Trastuzumab-induced cardiotoxicity in elderly women with HER-2-positive breast cancer: a meta-analysis of real-world data

Bibliography

• Burandt E , Sauter G . HER2 ASCO guidelines: The answer to everything? Pathologe 2010;31:285–91
   PubMed Web of Science ®Google Scholar
• Owens MA , Horten BC , Da Silva MM . HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004;5:63–9
   PubMedGoogle Scholar
• Slamon DJ , Clark GM , Wong SG , et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987;235:177–82
   PubMed Web of Science ®Google Scholar
• Andrulis IL , Bull SB , Blackstein ME , et al. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. Toronto breast cancer study group. J Clin Oncol 1998;16:1340–9
   PubMed Web of Science ®Google Scholar
• Zhao J , Liu H , Wang M , et al. Characteristics and prognosis for molecular breast cancer subtypes in Chinese women. J Surg Oncol 2009;100(2):89–94
   PubMed Web of Science ®Google Scholar
• Xing P , Li J , Jin F . A case-control study of reproductive factors associated with subtypes of breast cancer in Northeast China. Med Oncol 2010;27(3):926–31
   PubMed Web of Science ®Google Scholar
• Lin CH , Liau JY , Lu YS , et al. Molecular subtypes of breast cancer emerging in young women in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. Cancer Epidemiol Biomarkers Prev 2009;18(6):1807–14
   PubMed Web of Science ®Google Scholar
• World Health Organization . Towards an age-friendly world. Available from: http://www.who.int/ageing/en/
   Google Scholar
• Taipei Times . Taiwan’s population moves from ‘aging’ to ‘aged’: statistics. Available from: http://www.taipeitimes.com/News/taiwan/archives/2013/10/23/2003575197
   Google Scholar
• Alberg AJ , Singh S . Epidemiology of breast cancer in older women: implications for future healthcare. Drugs Aging 2001;18(10):761–72
   PubMed Web of Science ®Google Scholar
• Serrano C , Cortés J , De Mattos-Arruda L , et al. Trastuzumab-related cardiotoxicity in the elderly:A role for cardiovascular risk factors. Ann Oncol 2012;23:897–902
   PubMed Web of Science ®Google Scholar
• Balduzzi S , Mantarro S , Guarneri V , et al. Trastuzumab-containing regimens for metastatic breast cancer. Cochrane Database Syst Rev 2014;6
   Google Scholar
• Suter TM , Procter M , van Veldhuisen DJ , et al. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial. J Clin Oncol 2007;25(25):3859–65
   PubMed Web of Science ®Google Scholar
• Brollo J , Curigliano G , Disalvatore D , et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 2013;39(1):44–50
   PubMed Web of Science ®Google Scholar
• Bowles EJ , Wellman R , Feigelson HS , et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012;104:1293–305
   PubMed Web of Science ®Google Scholar
• Du XL , Xia R , Burau K , et al. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005. Med Oncol 2011(Suppl 1):S80–90
   Google Scholar
• Chavez-MacGregor M , Zhang N , Buchholz TA , et al. Trastuzumab-related cardiotoxicity among older patients with breast cancer. J Clin Oncol 2013;31(33):4222–8
   PubMed Web of Science ®Google Scholar
• Tarantini L , Cioffi G , Gori S , et al. Trastuzumab adjuvant chemotherapy and cardiotoxicity in real world women with breast cancer. J Card Fail 2012;18:113–19
   PubMed Web of Science ®Google Scholar
• Tsai HT , Isaacs C , Fu AZ , et al. Risk of cardiovascular adverse events from trastuzumab (Herceptin(®)) in elderly persons with breast cancer: a population-based study. Breast Cancer Res Treat 2014;144(1):163–70
   PubMed Web of Science ®Google Scholar
• The Cochrane Collaboration . Available from: http://www.cochrane.org [Last accessed 20 October 2014]
   Google Scholar
• Higgins JP , Altman DG , Sterne JA ; The Cochrane Collaboration . “Assessing risk of bias in included studies,” in Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0, Chapter 8 2011. Available from: http://handbook.cochrane.org/
   Google Scholar
• Schunemann H , Brozek J , Oxman A ; The GRADE Working Group . GRADE Handbook for Grading Quality of Evidence and Strength of Recommendation. version 3.2 2009. Available from: http://www.cc-ims.net/gradepro
   Google Scholar
• Cochrane Bias Methods Group . Tool to assess risk of bias in cohort Studies. Available from: https://bmg.cochrane.org/sites/bmg.cochrane.org/files/uploads/Tool%20to%20Assess%20Risk%20of%20Bias%20in%20Cohort%20Studies.pdf [Last accessed 10 October 2014]
   Google Scholar
• Piccart-Gebhart MJ , Procter M , Leyland-Jones B , et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N Engl J Med 2005;353(16):1659–72
   PubMed Web of Science ®Google Scholar
• Perez EA , Suman VJ , Davidson NE , et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J Clin Oncol 2008;26(8):1231–8
   PubMed Web of Science ®Google Scholar
• Smith I , Procter M , Gelber RD , et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007;369(9555):29–36
   PubMed Web of Science ®Google Scholar
• Romond EH , Jeong JH , Rastogi P , et al. Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with node-positive, human epidermal growth factor receptor 2-positive breast cancer. J Clin Oncol 2012;30(31):3792–9
   PubMed Web of Science ®Google Scholar
• Chen T , Xu T , Li Y , et al. Risk of cardiac dysfunction with trastuzumab in breast cancer patients: A meta-analysis. Cancer Treat Rev 2011;37(4):312–20
   PubMed Web of Science ®Google Scholar
• Dahabreh IJ , Linardou H , Siannis F , et al. Trastuzumab in the adjuvant treatment of early-stage breast cancer: a systematic review and meta-analysis of randomized controlled trials. Oncologist 2008;13:620–30
   PubMed Web of Science ®Google Scholar
• Viani GA , Afonso SL , Stefano EJ , et al. Adjuvant trastuzumab in the treatment of her-2-positive early breast cancer: a meta-analysis of published randomized trials. BMC Cancer 2007;7:153
   PubMed Web of Science ®Google Scholar
• Brollo J , Curigliano G , Disalvatore D , et al. Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev 2013;39(1):44–50
   PubMed Web of Science ®Google Scholar
• Serrano C , Cortes J , De Mattos-Arruda L , et al. Trastuzumab-related cardiotoxicity in the elderly: a role for cardiovascular risk factors. Ann Oncol 2012;23(4):897–902
   PubMed Web of Science ®Google Scholar
• Slamon D , Eiermann W , Robert N , et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med 2011;365:1273–83
   PubMed Web of Science ®Google Scholar
• Guarneri V , Lenihan DJ , Valero V , et al. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: The MD anderson cancer center experience. J Clin Oncol 2006;24:4107–15
   PubMed Web of Science ®Google Scholar
• Shen YC , Chang CJ , Hsu C , et al. Significant difference in the trends of female breast cancer incidence between Taiwanese and Caucasian Americans: implications from age-period-cohort analysis. Cancer Epidemiol Biomarkers Prev 2005;14(8):1986–90
   PubMed Web of Science ®Google Scholar
• Taiwan Today . Available from: heet://taiwantoday.tw/ct.asp?xItem=221377&ctNode=413 [Last accessed 10 November 2014]
   Google Scholar
• Muss H . Coming of age: breast cancer in seniors. Oncologist 2011;16(Suppl 1):79–87
   PubMed Web of Science ®Google Scholar
• Jones AL , Barlow M , Barrett-Lee PJ , et al. Management of cardiac health in trastuzumab-treated patients with breast cancer: updated United Kingdom national cancer research institute recommendations for monitoring. Br J Cancer 2009;100:684–92
   PubMed Web of Science ®Google Scholar